OncLive® On Air

S16 Ep30: ASH Guidelines Provide Key Recommendations for AYA Acute Lymphoblastic Leukemia Management: With Wendy Stock, MD

S16 Ep29: Novel Treatment Combinations for B-ALL May Help Patients Safely Achieve Remission: With Colin Vale, MD

S16 Ep28: Medical Crossfire®: Menin Inhibitors in AML—Dissecting the Data to Define the Role

S16 Ep26: Trans-Arterial Micro-Perfusion Could Boost Systemic Chemotherapy Efficacy in Unresectable Pancreatic Cancer: With Gregory J. Tiesi, MD, FACS, FSSO; Anthony Scholer, MD, FACS, FSSO; and Eric Pletcher, MD

S16 Ep27: Show Me the Data™—Closing Clinical Gaps in Gastric and Esophageal Cancer: Advancing Targeted Treatment Strategies Across the Care Continuum

Targeted therapies, immunotherapies, and chemotherapies are evolving the standard of care for gastric, esophageal, and gastroesophageal junction adenocarcinomas. The Matterhorn trial demonstrates that adding durvalumab to the FLOT chemotherapy backbone significantly improves event-free and overall survival in localized...

S16 Ep25: Exploring CAR T in Solid Tumors, Clinical Trials, and Cancer Incidence Questions

S16 Ep24: Tumor Board: Translating HER2 and TROP2 Innovations to Transform NSCLC Care

S16 Ep23: Show Me the Data™: Post-TKI Sequencing in EGFR-Mutated NSCLC—Optimizing Current Strategies and Preparing for New Treatment Modalities

Sequencing systemic therapy for EGFR-mutated non-small cell lung cancer following progression on first-line tyrosine kinase inhibitors requires a precise, molecularly-driven approach. Repeat biopsies, whether liquid or tissue-based, are essential to identify actionable resistance mechanisms such as MET amplification or...

S16 Ep22: Leading Breast Oncologists Share Advice and Optimism for Future Women in Oncology: With Kelly E. McCann, MD, PhD, and Sara Nunnery, MD, MSCI

S16 Ep21: FDA Approval Insights: SC Daratumumab Plus VRd Provides Additional Treatment Avenue in Transplant-Ineligible, Newly Diagnosed Myeloma: With Saad Z. Usmani, MD, MBA, FACP, FASCO

S16 Ep20: Medical Crossfire®: Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment

S16 Ep20: Incorporating TROP2-Targeted ADCs Into Lung Cancer Treatment Algorithms: With Eric K. Singhi, MD

S16 Ep19: Show Me the Data™: Incorporating the Latest Advances in Immunotherapy and EGFR-Targeted Treatments for Resectable Early-Stage NSCLC

S16 Ep18: Integrating Novel Targets and Translational Insights Into SCLC Practice: With Anne Chiang, MD, PhD

Small cell lung cancer treatment has entered a new era since 2018, moving beyond traditional chemotherapy toward immunotherapy and targeted strategies that significantly improve median overall survival. Dr. Anne Chiang highlights the importance of understanding disease heterogeneity, exemplified by the Phase 2 S2409 PR...

S16 Ep17: Breast Imaging Advances Emphasize the Importance of Patient-Focused Nuclear Medicine Collaboration: With Megan Kruse, MD; and Sophia O’Brien, MD

S16 Ep16: Cases and Conversations™: Navigating the New Immunotherapy Era in Squamous Cell Anal Carcinoma

S16 Ep15: Six-Year CheckMate 9LA Data Reinforce Durable Survival in Metastatic NSCLC: With David Carbone, MD, PhD

S16 Ep14: Pumitamig Represents Potential Immunotherapy Strategy for TNBC: With Sarah Sammons, MD

S16 Ep13: Positive Phase 3 Data Drive Varegacestat Development in Desmoid Tumors: With Rashmi Chugh MD

S16 Ep11: Expert Illustrations & Commentaries: Translating the Science of Bispecific Antibodies in Solid Tumors – From Mechanisms to Emerging Data